Advances in positive inotropic therapy: Levosimendan *
- 1 September 2003
- journal article
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 31 (9) , 2408-2409
- https://doi.org/10.1097/01.ccm.0000084861.07091.f3
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Effects of levosimendan on right ventricular function and ventriculovascular coupling in open chest pigs*Critical Care Medicine, 2003
- Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN)European Heart Journal, 2002
- Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trialThe Lancet, 2002
- LevosimendanDrugs, 2001
- Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failureJournal of the American College of Cardiology, 2000
- Acute Hemodynamic and Clinical Effects of Levosimendan in Patients With Severe Heart FailureCirculation, 2000
- Levosimendan: A promising agent for the treatment of hospitalized patients with decompensated heart failureCurrent Cardiology Reports, 2000
- Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytesEuropean Journal of Pharmacology, 1997
- Effect of Oral Milrinone on Mortality in Severe Chronic Heart FailureNew England Journal of Medicine, 1991